




Structure and Content of Clinical Study Reports

Dr. Jo White

Structure & Content of Clinical Study Report

As in Good Clinical Practices overview,
follow **ICH** guidance

- Provides complete information about study
 - ▶ *Organized so the most important information is the most accessible*
- Allows for comparability of different studies
- Accepted by all countries/regions and all regulatory agencies



Title page gives extensive information, including:

Formal Title of Report

Investigational Product Studied

Sponsor

Relevant Dates

Condition/Indication Studied

Protocol Identification (Code #)

Development Phase of the Clinical Trial

Names of Principal Individuals – Chief Investigator,

Medical Officer, Sponsor Signatory



Three Broad Divisions of the Report

- Introductory material

Most important!

- Substantive information on the study

- Annexes / appendices



Opening Pages of Report ... Preliminary Material

- Study Synopsis
 - ▶ *Like executive summary, 3-page maximum*
 - ▶ *Should include numerical data to illustrate results, not just text or p-values*
- Table of Contents, Glossary
 - ▶ *Abbreviations, acronyms, definitions of key terms*



Preliminary Material (Continued)

- Statement of Ethics
- Administrative Structure, List of Investigators
- Introduction
 - ▶ One page only
 - ▶ *Enough information to place study in context, state important guidelines*
- Study Objectives
 - ▶ Overall purpose of the study



Now Comes the Main Body of the Report



Corresponds with Sections 9 through 13 in ICH
“Structure & Content” document



Section 9-Investigational Plan

- Full discussion & description of study design, plan
 - Criteria for both inclusion & exclusion of study subjects
 - Treatments administered, efficacy & safety variables, quality assurance information
 - Statistical basis; notes on any changes to original concept
 - Clearly account for all patients who entered the study, including any who discontinued their participation
- ## Section 10-Study Patients (subjects)
- Document all deviations from protocol



Section 11-Efficacy Evaluation

- Data sets analyzed
- Baseline characteristics of subjects; treatment compliance
- Report & tabulate results, including statistical adjustments if appropriate
- Information on individual response, drug concentration, interactions, etc.

Section 12-Safety Evaluation

- **Make particular note of adverse events, especially SAEs**
- Clinical laboratory evaluation



Section 13-Discussion & Overall Conclusions

This can and should be brief! Provide a concise text summary of the study results.

Make special note of unanticipated occurrences.

Refer report recipients to tables, etc. in the Appendix for more detailed information.



Now we're ready to wrap this up . . .

The remaining sections of the report are basically supplementary

Many people who get the report may not even look at these final addenda

BUT maintain high professionalism in completing these last necessary pieces



Reference List

- Refer readers to literature with relevance to the study

Tables, Figures, Graphs

- A section for more detailed data, expanding the information provided in the main body of the report
- Also, an opportunity to make special note of certain unique aspects of the study

Appendices

- Investigator list, protocol specifics, notes on study subjects, sample forms, etc.

